Therapeutic strategies in epithelial ovarian cancer

被引:0
作者
Ayako Kim
Yutaka Ueda
Tetsuji Naka
Takayuki Enomoto
机构
[1] Osaka University Graduate School of Medicine,Department of Obstetrics and Gynecology
[2] National Institute of Biomedical Innovation,Laboratory for Immune Signal
来源
Journal of Experimental & Clinical Cancer Research | / 31卷
关键词
Review; ovarian cancer; conventional treatment; novel treatment; clear cell carcinoma; bevacizumab; PARP inhibitor;
D O I
暂无
中图分类号
学科分类号
摘要
Ovarian cancer is the most lethal gynecologic malignancy. It appears that the vast majority of what seem to be primary epithelial ovarian and primary peritoneal carcinomas is, in fact, secondary from the fimbria, the most distal part of the fallopian tube.
引用
收藏
相关论文
共 167 条
[1]  
Kurman RJ(2010)The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory Am J Surg Pathol 34 433-443
[2]  
Shih Ie M(1999)Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings Obstet Gynecol 93 21-24
[3]  
Rubin SC(2009)Ovarian cancer Lancet 374 1371-82
[4]  
Randall TC(2004)Ovarian tumorigenesis: a proposed 1 model based on orphological and molecular genetic analysis Am J Pathol 164 1511-1518
[5]  
Armstrong KA(2008)Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis Am J Obstet Gynecol 198 351-356
[6]  
Chi DS(2009)Ovarian cancer Annu Rev Pathol 4 287-313
[7]  
Hoskins WJ(2008)The cell of origin of ovarian epithelial tumours Lancet Oncol 9 1191-112
[8]  
Hennessy BT(2003)International Collaborative Ovarian Neoplasm trial and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma J Natl Cancer Inst 95 105-953
[9]  
Coleman RL(2010)Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med 363 943-1805
[10]  
Markman M(1991)Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin J Clin Oncol 9 1801-426